navajojoe wrote: canyousayiii wrote: Sounds to me like Jilly had not invested in publicly listed companies on a senior exchange. I will catch up to the AGM stuff later, but if true that there were again no opportunities to ask real questions, Ghezzi is then showing that he is not fit for the CEO role of a publicly listed company. He recognized he made mistakes earlier but that recognition seems to have been to pacify the shareholders while he continues the same modus operandi. He would be a great executive VP or a COO for the core business IMO. I have seen a situation where some investors got fed up and ultimately the OSC asked some tough questions. I would think that it would be a lot more efficient and effective for a company to just answer some questions during these webinars then potentially getting on the OSC radar and taking much more time to answer to them before they provide those updates to shareholders afterwards. If Ghezzi is not going to answer shareholder questions, then IMO he needs to get much better on providing updates covering the things that he knows shareholders want to know about.
There was no phone number provided for anyone to phone a question in, but the login page for the webinar gave the email address for anyone who had a question, so that mislead me to believe they might at least answer some softball questions. I have no idea why that was there, because anyone interested in KNR already had that email address, and have probably asked more than a few questions, most likely with little or no response, as I have epxerienced.
It is becoming more and more obvious that they are not answering questions because they simply don't have any response other than BioCloud sales suck big time, and pretty much everything else remains up in the air.
So we have to be satisfied with crumbs. Watch for a news release about September revenue. They announced the August number because it was pretty good. If we don't hear about the September top line, we can assume it sucks and August was a one-off.
So here we are at the end of September, still waiting for the Health Canada report that was originally supposed to be out in July, over 2 months late. One has to wonder what is going on.
There are so many avenues for good news from KNR, the really amazing thing is that so little comes from any of it.
The fall back position is that the core business appears to have some legs, so there is fundamental value there. The problem is we still have the liars on "the other board", and the odd one here, claiming that that business is worth multiples of today's share price, which is totally laughable. Based on that business alone, KNR should be worth $2 at some point in the future, but I won't be hanging around for that. If BioCloud is a bust, most investors will join me in saying goodbye, and good riddance.
JMO